365 related articles for article (PubMed ID: 32535906)
21. If it's a target, it's a pan-cancer target: Tissue is not the issue.
Adashek JJ; Kato S; Sicklick JK; Lippman SM; Kurzrock R
Cancer Treat Rev; 2024 Apr; 125():102721. PubMed ID: 38522181
[TBL] [Abstract][Full Text] [Related]
22. Tissue-agnostic drug approvals: how does this apply to patients with breast cancer?
Weis LN; Tolaney SM; Barrios CH; Barroso-Sousa R
NPJ Breast Cancer; 2021 Sep; 7(1):120. PubMed ID: 34518552
[TBL] [Abstract][Full Text] [Related]
23. Impact of tissue-agnostic approvals for patients with sarcoma.
Pestana RC; Beal JR; Parkes A; Hamerschlak N; Subbiah V
Trends Cancer; 2022 Feb; 8(2):135-144. PubMed ID: 34887213
[TBL] [Abstract][Full Text] [Related]
24. U.S. Food and Drug Administration anticancer drug approval trends from 2016 to 2018 for lung, colorectal, breast, and prostate cancer.
Ribeiro TB; Ribeiro A; Rodrigues LO; Harada G; Nobre MRC
Int J Technol Assess Health Care; 2020; 36(1):20-28. PubMed ID: 31775939
[TBL] [Abstract][Full Text] [Related]
25. Agnostic Approvals in Oncology: Getting the Right Drug to the Right Patient with the Right Genomics.
Tateo V; Marchese PV; Mollica V; Massari F; Kurzrock R; Adashek JJ
Pharmaceuticals (Basel); 2023 Apr; 16(4):. PubMed ID: 37111371
[TBL] [Abstract][Full Text] [Related]
26. JSCO-ESMO-ASCO-JSMO-TOS: international expert consensus recommendations for tumour-agnostic treatments in patients with solid tumours with microsatellite instability or NTRK fusions.
Yoshino T; Pentheroudakis G; Mishima S; Overman MJ; Yeh KH; Baba E; Naito Y; Calvo F; Saxena A; Chen LT; Takeda M; Cervantes A; Taniguchi H; Yoshida K; Kodera Y; Kitagawa Y; Tabernero J; Burris H; Douillard JY
Ann Oncol; 2020 Jul; 31(7):861-872. PubMed ID: 32272210
[TBL] [Abstract][Full Text] [Related]
27. Tumor-Agnostic Treatment for Cancer: When How is Better than Where.
Lavacchi D; Roviello G; D'Angelo A
Clin Drug Investig; 2020 Jun; 40(6):519-527. PubMed ID: 32307639
[TBL] [Abstract][Full Text] [Related]
28. Tumor-Agnostic Approvals: Insights and Practical Considerations.
Lu CC; Beckman RA; Li XN; Zhang W; Jiang Q; Marchenko O; Sun Z; Tian H; Ye J; Yuan SS; Yung G;
Clin Cancer Res; 2024 Feb; 30(3):480-488. PubMed ID: 37792436
[TBL] [Abstract][Full Text] [Related]
29. Properties of FDA-approved small molecule protein kinase inhibitors: A 2020 update.
Roskoski R
Pharmacol Res; 2020 Feb; 152():104609. PubMed ID: 31862477
[TBL] [Abstract][Full Text] [Related]
30. Impact of tissue-agnostic approvals for patients with gastrointestinal malignancies.
Bhamidipati D; Subbiah V
Trends Cancer; 2023 Mar; 9(3):237-249. PubMed ID: 36494311
[TBL] [Abstract][Full Text] [Related]
31. The evolving paradigm of biomarker actionability: Histology-agnosticism as a spectrum, rather than a binary quality.
Tarantino P; Mazzarella L; Marra A; Trapani D; Curigliano G
Cancer Treat Rev; 2021 Mar; 94():102169. PubMed ID: 33652262
[TBL] [Abstract][Full Text] [Related]
32. Clinical Trial Evidence Supporting US Food and Drug Administration Approval of Novel Cancer Therapies Between 2000 and 2016.
Ladanie A; Schmitt AM; Speich B; Naudet F; Agarwal A; Pereira TV; Sclafani F; Herbrand AK; Briel M; Martin-Liberal J; Schmid T; Ewald H; Ioannidis JPA; Bucher HC; Kasenda B; Hemkens LG
JAMA Netw Open; 2020 Nov; 3(11):e2024406. PubMed ID: 33170262
[TBL] [Abstract][Full Text] [Related]
33. A Comparison of Post-marketing Measures Imposed by Regulatory Agencies to Confirm the Tissue-Agnostic Approach.
Mulder J; van Stuijvenberg OC; van Hennik PB; Voest EE; Pasmooij AMG; Stoyanova-Beninska V; de Boer A
Front Med (Lausanne); 2022; 9():893400. PubMed ID: 35775007
[TBL] [Abstract][Full Text] [Related]
34. Trends in the approval of cancer therapies by the FDA in the twenty-first century.
Scott EC; Baines AC; Gong Y; Moore R; Pamuk GE; Saber H; Subedee A; Thompson MD; Xiao W; Pazdur R; Rao VA; Schneider J; Beaver JA
Nat Rev Drug Discov; 2023 Aug; 22(8):625-640. PubMed ID: 37344568
[TBL] [Abstract][Full Text] [Related]
35. Impact of tissue-agnostic approvals on management of primary brain tumors.
Ahluwalia MS; Khosla AA; Ozair A; Gouda MA; Subbiah V
Trends Cancer; 2024 Mar; 10(3):256-274. PubMed ID: 38245379
[TBL] [Abstract][Full Text] [Related]
36. [The application of target-based tissue-agnostic therapy in the treatment of lung cancer].
Peták I
Magy Onkol; 2020 Sep; 64(3):206-215. PubMed ID: 32966351
[TBL] [Abstract][Full Text] [Related]
37. Approvals in 2018: a histology-agnostic new molecular entity, novel end points and real-time review.
Blumenthal GM; Pazdur R
Nat Rev Clin Oncol; 2019 Mar; 16(3):139-141. PubMed ID: 30670830
[No Abstract] [Full Text] [Related]
38. TRK Inhibitors: Tissue-Agnostic Anti-Cancer Drugs.
Han SY
Pharmaceuticals (Basel); 2021 Jun; 14(7):. PubMed ID: 34209967
[TBL] [Abstract][Full Text] [Related]
39. Histology-Agnostic Drugs: A Paradigm Shift-A Narrative Review.
Mansinho A; Fernandes RM; Carneiro AV
Adv Ther; 2023 Apr; 40(4):1379-1392. PubMed ID: 36418841
[TBL] [Abstract][Full Text] [Related]
40. A paradigm shift in biomarker guided oncology drug development.
Jørgensen JT
Ann Transl Med; 2019 Apr; 7(7):148. PubMed ID: 31157269
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
